Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.39 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl Alcohol SCHEMBL28286625 | 0.96 | ALDH1A1 (0.39) | ALDH1A1POLBGBA1RAB9ASMN1; SMN2 | |
| SCHEMBL448797 | 0.96 | ALDH1A1 (0.41) | ALDH1A1POLBGBA1RAB9ASMN1; SMN2 | |
| SCHEMBL1491164 | 0.94 | ALDH1A1 (0.40) | ALDH1A1POLBGBA1RAB9ASMN1; SMN2 | |
| SCHEMBL3950950 | 0.94 | ALDH1A1 (0.40) | ALDH1A1POLBGBA1RAB9ASMN1; SMN2 | |
| SCHEMBL22722 | 0.91 | GBA1 (0.42) | GBA1LTB4RLTB4R2 | |
| SCHEMBL5269537 | 0.82 | GBA1 (0.42) | GBA1 | |
| SCHEMBL7197655 | 0.80 | TSHR (0.56) | POLB | |
| SCHEMBL1558896 | 0.79 | LTB4R (0.44) | GBA1LTB4RLTB4R2 | |
| SCHEMBL30754350 | 0.79 | LTB4R (0.44) | GBA1LTB4RLTB4R2 | |
| SCHEMBL1773236 | 0.79 | MEN1 (0.41) | ALDH1A1POLBRAB9ASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114830395-B | Nonaqueous electrolyte secondary battery | 松下知识产权经营株式会社 | 2025-02-11 | — | — | CN | claimed |
| CN-111116604-A | Process method for preparing fluorescamine | 苏州百灵威超精细材料有限公司 | 2020-05-08 | — | — | CN | claimed |
| US-20130102641-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2013-04-25 | — | — | US | claimed |
| US-7790708-B2 | Prodrugs of GABA analogs, compositions and uses thereof | XENOPORT, INC. (US) | 2010-09-07 | — | — | US | claimed |
| US-20090105292-A9 | Glucocorticoid Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2009-04-23 | — | — | US | claimed |
| EP-1902714-A1 | Prodrugs of gaba analogs, compositions and uses thereof | Xenoport, Inc. (US) | 2008-03-26 | — | — | EP | claimed |
| US-20070281959-A1 | Glucocorticoid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2007-12-06 | — | — | US | claimed |
| EP-1404324-B1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT INC (US) | 2007-12-05 | — | — | EP | claimed |
| EP-1718653-A1 | GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY | Ligand Pharmaceuticals Inc. (US) | 2006-11-08 | — | — | EP | claimed |
| US-7060727-B2 | Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof | XENOPORT, INC. (US) | 2006-06-13 | — | — | US | claimed |
| WO-2005082909-A1 | GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2005-09-09 | — | — | WO | claimed |
| US-20040147455-A1 | Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof | XENOPORT, INC. | 2004-07-29 | — | — | US | claimed |
| WO-2004052360-A1 | PRODRUGS OF FUSED GABA ANALOGS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2004-06-24 | — | — | WO | claimed |
| US-20030176398-A1 | Prodrugs of GABA analogs, compositions and uses thereof | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2003-09-18 | — | — | US | claimed |
| EP-0586394-A1 | METHYL ESTERS OF ALDIMINO- OR KETIMINO-OXY-ORTHOTOLYLACRYLIC ACID, MANUFACTURING PROCESS AND FUNGICIDES CONTAINING THEM | CIBA-GEIGY AG (CH) | 1994-03-16 | — | — | EP | claimed |
| WO-1992018494-A1 | METHYL ESTERS OF ALDIMINO- OR KETIMINO-OXY-ORTHOTOLYLACRYLIC ACID, MANUFACTURING PROCESS AND FUNGICIDES CONTAINING THEM | CIBA-GEIGY AG (CH) | 1992-10-29 | — | — | WO | claimed |
| EP-4665718-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | Apogee Pharmaceuticals, Inc. (CA) | 2025-12-24 | — | — | EP | disclosed |
| US-12378231-B2 | Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof | APOGEE PHARMACEUTICALS, INC. (CA) | 2025-08-05 | — | — | US | disclosed |
| EP-0132392-A2 | Asymmetric synthesis of alpha-substituted-alpha-cyanomethyl alcohols | ICI AUSTRALIA LIMITED (AU) | 1985-01-30 | — | — | EP | disclosed |
| US-4000311-A | Substituted 1,3-benzodioxane agents for the control of plant bacteria | CIBA-GEIGY CORPORATION (US) | 1976-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378231-B2 | Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof | MGLL, PNLIP, LPL | ALDH1A1 530/4885POLB 760/4885GBA1 53/4885 |
| US-20130102641-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | GABRB1, GABRB2, GABRB3 | ALDH1A1 298/4885POLB 3243/4885GBA1 398/4885 |
| US-20090105292-A9 | Glucocorticoid Receptor Modulator Compounds and Methods | NR3C1, NR3C2, MC2R | ALDH1A1 1465/4885POLB 3867/4885GBA1 1801/4885 |
| US-20070281959-A1 | Glucocorticoid receptor modulator compounds and methods | NR3C1, NR3C2, MC2R | ALDH1A1 1465/4885POLB 3867/4885GBA1 1801/4885 |
| US-20030176398-A1 | Prodrugs of GABA analogs, compositions and uses thereof | GABRB1, GABRB2, GABRB3 | ALDH1A1 298/4885POLB 3243/4885GBA1 398/4885 |
| US-20040147455-A1 | Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof | GABRB1, GABRB2, GABRB3 | ALDH1A1 380/4885POLB 3280/4885GBA1 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.